CN1444481A - 蛋白酶抑制剂 - Google Patents

蛋白酶抑制剂 Download PDF

Info

Publication number
CN1444481A
CN1444481A CN01813500A CN01813500A CN1444481A CN 1444481 A CN1444481 A CN 1444481A CN 01813500 A CN01813500 A CN 01813500A CN 01813500 A CN01813500 A CN 01813500A CN 1444481 A CN1444481 A CN 1444481A
Authority
CN
China
Prior art keywords
methyl
oxo
butyl
amide
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01813500A
Other languages
English (en)
Chinese (zh)
Inventor
小罗伯特·W·马奎斯
汝玉
丹尼尔·F·维伯
马克斯韦尔·D·卡明斯
斯科特·K·汤普森
丹尼斯·亚马什塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1444481A publication Critical patent/CN1444481A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01813500A 2000-06-14 2001-06-14 蛋白酶抑制剂 Pending CN1444481A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59384500A 2000-06-14 2000-06-14
US09/593,845 2000-06-14

Publications (1)

Publication Number Publication Date
CN1444481A true CN1444481A (zh) 2003-09-24

Family

ID=24376433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01813500A Pending CN1444481A (zh) 2000-06-14 2001-06-14 蛋白酶抑制剂

Country Status (25)

Country Link
EP (1) EP1307204A4 (fr)
JP (1) JP2004503502A (fr)
KR (1) KR20030008220A (fr)
CN (1) CN1444481A (fr)
AP (1) AP2002002671A0 (fr)
AR (1) AR032622A1 (fr)
AU (1) AU2001268407A1 (fr)
BG (1) BG107327A (fr)
BR (1) BR0111693A (fr)
CA (1) CA2412353A1 (fr)
CZ (1) CZ20024086A3 (fr)
EA (1) EA200300018A1 (fr)
EC (1) ECSP024388A (fr)
HU (1) HUP0301231A2 (fr)
IL (1) IL153421A0 (fr)
MA (1) MA25758A1 (fr)
MX (1) MXPA02012442A (fr)
NO (1) NO20025786L (fr)
NZ (1) NZ522965A (fr)
OA (1) OA12288A (fr)
PE (1) PE20011374A1 (fr)
PL (1) PL360508A1 (fr)
SK (1) SK17592002A3 (fr)
WO (1) WO2001095911A1 (fr)
ZA (1) ZA200209808B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1231922A4 (fr) * 1999-11-10 2004-06-23 Smithkline Beecham Corp Inhibiteurs de protease
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
CA2436850A1 (fr) * 2000-11-22 2003-07-03 Smithkline Beecham Corporation Inhibiteurs de la protease
CA2437409C (fr) 2001-02-20 2010-10-19 Chugai Seiyaku Kabushiki Kaisha Azoles en inhibiteurs de la decarboxylase des malonyl-coa, convenant comme modulateurs metaboliques
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
EP1401453A4 (fr) * 2001-05-17 2005-04-06 Smithkline Beecham Corp Inhibiteurs de protease
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
CA2533747C (fr) * 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Composes heterocycliques utiles comme inhibiteurs de la malonyl-coa decarboxylase
CA2533749C (fr) 2003-08-01 2012-07-10 Chugai Seiyaku Kabushiki Kaisha Composes de piperidine utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
US7786145B2 (en) 2003-08-01 2010-08-31 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
EP2719700A1 (fr) 2008-01-09 2014-04-16 Amura Therapeutics Limited Derives de tetrhydrofur(3,2-b)pyrrol-3-one comme inhibiteurs des proteases de cysteine
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
US9427441B2 (en) 2014-02-19 2016-08-30 Indiana University Research And Technology Corporation Targeting primary cilia to treat glaucoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
WO2000038687A1 (fr) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Inhibiteurs de proteases
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO2001034565A2 (fr) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Inhibiteurs de protease
JP2004509083A (ja) * 2000-09-01 2004-03-25 スミスクライン・ビーチャム・コーポレイション 治療方法
CA2436850A1 (fr) * 2000-11-22 2003-07-03 Smithkline Beecham Corporation Inhibiteurs de la protease
EP1401453A4 (fr) * 2001-05-17 2005-04-06 Smithkline Beecham Corp Inhibiteurs de protease

Also Published As

Publication number Publication date
OA12288A (en) 2003-12-12
SK17592002A3 (sk) 2003-05-02
CA2412353A1 (fr) 2001-12-20
CZ20024086A3 (cs) 2003-05-14
ECSP024388A (es) 2003-02-06
AR032622A1 (es) 2003-11-19
KR20030008220A (ko) 2003-01-24
NO20025786L (no) 2003-02-12
HUP0301231A2 (hu) 2003-08-28
NO20025786D0 (no) 2002-12-02
BR0111693A (pt) 2004-04-06
EP1307204A4 (fr) 2004-06-02
PL360508A1 (en) 2004-09-06
WO2001095911A1 (fr) 2001-12-20
BG107327A (bg) 2003-07-31
MXPA02012442A (es) 2003-04-25
AU2001268407A1 (en) 2001-12-24
ZA200209808B (en) 2004-07-09
EA200300018A1 (ru) 2003-06-26
JP2004503502A (ja) 2004-02-05
MA25758A1 (fr) 2003-04-01
EP1307204A1 (fr) 2003-05-07
PE20011374A1 (es) 2002-04-07
NZ522965A (en) 2004-06-25
IL153421A0 (en) 2003-07-06
AP2002002671A0 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
CN1253441C (zh) 蛋白酶抑制剂
CN1416346A (zh) 蛋白酶抑制剂
CN1177821C (zh) 基质金属蛋白酶抑制剂
CN1171870C (zh) 半胱氨酸蛋白酶抑制剂
CN1213040C (zh) 丝氨酸蛋白酶抑制剂
CA2289010A1 (fr) Inhibiteurs de proteases
CN101027295A (zh) 用于治疗炎性疾病的化合物和含它们的药物组合物
AU2001243441A1 (en) Protease inhibitors
CN1444481A (zh) 蛋白酶抑制剂
CN1431904A (zh) 蛋白酶抑制剂
US7405209B2 (en) Protease inhibitors
CN1635903A (zh) 蛋白酶抑制剂
EP1384713A1 (fr) Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
MXPA01006613A (en) Protease inhibitors
HK1166322A1 (en) Proline derivatives as cathepsin inhibitors
HK1166322B (en) Proline derivatives as cathepsin inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication